Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

Inclusion Criteria: * Confirmed new diagnosis of Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukemia * Male or female patients aged 18-55 years * Not previously treated except for prephase (corticosteroids, cyclophosphamide, single dose VCR will be permitted) therapy during establishment of the diagnosis * Signed written inform consent, willingness and ability to comply with all study procedures * Molecular detection of BCR-ABL transcripts * Willingness of women of child-bearing potential (WOCBP) and male subjects whose sexual partners are WOCBP, to use an effective form of contraception (pearl index \< 1%), such as complete sexual abstinence, combined oral contraceptive, hormone IUCD, vaginal hormone ring, transdermal contraceptive patch, contraceptive implant or depot contraceptive injection in combination with a second method of contraception like a condom or a cervical cap / diaphragm with spermicide or surgical sterilisation (vasectomy) in male patients or male partners during the study and at least 6 months thereafter. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or surgical sterilization or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). * Negative pregnancy test for women of child-bearing potential. Exclusion Criteria: * Patients with ECOG status \> 2 * Patients with QTcF \> 470 ms * Cardiac insufficiency NYHA grade III/IV, LEVF \< 50%, myocardial infarction within the past 6 months prior to study * Active secondary malignancy requiring treatment * Patients with active, uncontrolled bacterial, viral or fungal infection * Known infection with HIV, Hepatitis B (except post vaccinal profile) or C * Inadequate hepatic functions defined as ASAT or ALAT \> 2,5 times the institutional upper limit of normal and total bilirubin \> 2 fold the institutional upper limit unless considered to be due to organ involvement by the leukemia * Concurrent severe diseases which exclude the administration of therapy * Expected non-compliance or inability to understand informed consent * Female patients who are pregnant or breast feeding * Treatment with other investigational antileukemic agents after informed consent.